Erste Asset Management GmbH Decreases Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Erste Asset Management GmbH trimmed its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 25.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 692,600 shares of the company's stock after selling 240,000 shares during the quarter. Erste Asset Management GmbH owned approximately 0.56% of Guardant Health worth $21,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. R Squared Ltd bought a new stake in Guardant Health during the fourth quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Guardant Health in the 3rd quarter valued at about $34,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health during the 4th quarter valued at about $43,000. Jones Financial Companies Lllp grew its stake in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after purchasing an additional 817 shares during the period. Finally, Van ECK Associates Corp grew its stake in Guardant Health by 47.4% during the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock worth $88,000 after purchasing an additional 929 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GH. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Guggenheim reaffirmed a "buy" rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Piper Sandler increased their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Barclays initiated coverage on Guardant Health in a research report on Thursday, January 23rd. They issued an "overweight" rating and a $60.00 target price for the company. Finally, The Goldman Sachs Group increased their price target on Guardant Health from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Twenty equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $48.40.

Remove Ads

Guardant Health Stock Up 0.0 %

GH stock traded up $0.01 during trading on Monday, reaching $42.90. The stock had a trading volume of 1,529,039 shares, compared to its average volume of 2,140,120. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.89. The company's 50 day moving average is $43.01 and its two-hundred day moving average is $32.94. The company has a market capitalization of $5.29 billion, a price-to-earnings ratio of -12.05 and a beta of 1.50.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. As a group, research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.